Contact|Careers EN|ES About us eASC Technology Platform Products Investors Newsroom Company TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programmes, and a commercialised product. The stem cell programmes are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency. CX601 is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease. Cx611 has successfully concluded a Phase IIa trial in rheumatoid arthritis, and is now in development for early rheumatoid arthritis and for severe sepsis. The company’s commercialised product, ChondroCelect®, for cartilage repair in the knee, was the first approved cell-based product in Europe, and is marketed and distributed by Swedish Orphan Biovitrum AB (‘Sobi’, NASDAQ OMX Stockholm: SOBI) and Finnish Red Cross Blood Service (FRCBS)﻿. TiGenix is based in Leuven, Belgium, and has operations in Madrid , Spain. Read more... Products Read more... Latest News 15 September 2014 - Tigenix to participate or present at key conferences in H2 2014 (EN - NL - FR) 8 September 2014 - European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601 (EN - NL - FR) 1 September 2014 - TiGenix appoints Chief Medical Officer and Vice President Medical Affairs and New Product Commercialisation (EN - NL - FR) 27 August 2014 - Correction to H1 2014 Business and Financial Update (EN - NL - FR) 26 August 2014 - H1 2014 Business and Financial Update (EN - NL - FR) - Presentation - 2014 Interim Financial Statements ENG - 2014 Interim Financial Statements NL Read more... Events Cx611 Development Plan webcast presentation 30 June 2014 R&D Media Briefing, 30 June 2014 9th edition European Smallcap Event, April 7-8, Paris, France 9th Annual World Stem Cell & Regenerative Medicine Congress May 20-22, London, UK BioEquity Europe 2014 May 21-22, Amsterdam, the Netherlands Read more... © 2014 TiGenix - Legal - Privacy Policy

Contact|Careers EN|ES About us eASC Technology Platform Products Investors Newsroom Contact First name * Name * E-mail * Company * Message * Inquiries General inquiries: info@tigenix.com Medical inquiries: medinfo@tigenix.com Investor inquiries: investor@tigenix.com Privacy requests: privacy@tigenix.com Job applications: careers@tigenix.com TiGenix Headquarters: Leuven, Belgium TiGenix NV Haasrode Researchpark 1724 Romeinse straat 12 bus 2 3001 Leuven Belgium Road map (pdf) Tel: +32 (0) 16 39 60 60 Fax: +32 (0) 16 39 79 70 TiGenix SAU, Madrid, Spain Calle Marconi, 1 Parque Tecnológico de Madrid Tres Cantos 28760 Madrid Spain Road map (pdf) Tel: +34 (0) 91 804 92 64 Fax: +34 (0) 91 804 92 63 PDF CREATOR Add this page to your PDF You have added 0 page(s) to your PDF. Download your PDF © 2014 TiGenix - Legal - Privacy Policy